What is the current valuation of the China Radioligand Therapy Rlt Market?

As of 2024, the market valuation was 0.611 USD Billion. Read More

What is the projected market size for the China Radioligand Therapy Rlt Market by 2035?

The market is expected to reach a valuation of 1.5 USD Billion by 2035. Read More

What is the expected CAGR for the China Radioligand Therapy Rlt Market during the forecast period?

The anticipated CAGR for the market from 2025 to 2035 is 8.52%. Read More

Which applications dominate the China Radioligand Therapy Rlt Market?

Oncology leads the market with a valuation projected to grow from 0.3055 to 0.75 USD Billion. Read More

What types of radioligands are utilized in the China market?

Alpha and Beta Emitters are expected to each grow from 0.183 to 0.45 USD Billion. Read More

How is the market segmented by administration route?

The intravenous route is projected to increase from 0.244 to 0.6 USD Billion. Read More

What are the primary target diseases in the China Radioligand Therapy Rlt Market?

Prostate cancer is anticipated to grow from 0.25 to 0.6 USD Billion. Read More

How does the market perform across different patient demographics?

Adult patients represent a significant segment, with growth from 0.3055 to 0.75 USD Billion. Read More

Who are the key players in the China Radioligand Therapy Rlt Market?

Prominent companies include Novartis, Bayer, and Eli Lilly, among others. Read More

What is the growth outlook for the China Radioligand Therapy Rlt Market?

The market appears poised for robust growth, driven by advancements in radioligand therapies. Read More

China Radioligand Therapy Market

China Radioligand Therapy RLT Market Research Report: Size, Share, Trend Analysis By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End Users (Hospitals & Clinics, Diagnostic Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

8.52%

2024 Market Size

$ 0.61 Billion

2035 Market Size

$ 1.5 Billion

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/50338-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Neurology
  4. 4.1.4 Endocrinology
2. 4.2 Healthcare, BY Type of Radioligand (USD Billion)
  1. 4.2.1 Alpha Emitters
  2. 4.2.2 Beta Emitters
  3. 4.2.3 Auger Electron Emitters
  4. 4.2.4 Radionuclide Therapy
3. 4.3 Healthcare, BY Administration Route (USD Billion)
  1. 4.3.1 Intravenous
  2. 4.3.2 Oral
  3. 4.3.3 Subcutaneous
4. 4.4 Healthcare, BY Target Disease (USD Billion)
  1. 4.4.1 Prostate Cancer
  2. 4.4.2 Neuroendocrine Tumors
  3. 4.4.3 Lymphoma
  4. 4.4.4 Thyroid Cancer
5. 4.5 Healthcare, BY Patient Demographics (USD Billion)
  1. 4.5.1 Pediatric Patients
  2. 4.5.2 Adult Patients
  3. 4.5.3 Geriatric Patients
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Ipsen (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck KGaA (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Siemens Healthineers (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY APPLICATION
3. 6.3 CHINA MARKET ANALYSIS BY TYPE OF RADIOLIGAND
4. 6.4 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
5. 6.5 CHINA MARKET ANALYSIS BY TARGET DISEASE
6. 6.6 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY TYPE OF RADIOLIGAND, 2026-2035 (USD Billion)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
  4. 7.2.4 BY TARGET DISEASE, 2026-2035 (USD Billion)
  5. 7.2.5 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Radioligand Therapy Market Segmentation

China Radioligand Therapy Market By Application (USD Billion, 2026-2035)

Oncology
Cardiology
Neurology
Endocrinology

China Radioligand Therapy Market By Type of Radioligand (USD Billion, 2026-2035)

Alpha Emitters
Beta Emitters
Auger Electron Emitters
Radionuclide Therapy

China Radioligand Therapy Market By Administration Route (USD Billion, 2026-2035)

Intravenous
Oral
Subcutaneous

China Radioligand Therapy Market By Target Disease (USD Billion, 2026-2035)

Prostate Cancer
Neuroendocrine Tumors
Lymphoma
Thyroid Cancer

China Radioligand Therapy Market By Patient Demographics (USD Billion, 2026-2035)

Pediatric Patients
Adult Patients
Geriatric Patients

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”